ConvaTec Group Plc — LSE:CTEC closed 0.26% lower on04 September 2026, with the shares at 226.80p after a decline of 0.60p on the day.
Smith & Nephew Plc — LSE:SN. closed 0.48% higher on04 September 2026, with the shares at 1,057.00p after a gain of 5.00p on the day.
The key question is whether the interim results due on 9 September 2026 confirm that last year's step-change in revenue, margins and profit was the start of a durable trend rather than a one-off lift from the Bio-Vet acquisition.
With aMarket Capitalisationof around £192m and shares at roughly 400p on 2 September 2026, according to lse.co.uk, the question is whether a consistent, cash-generative AIM company with a growing United States footprint is still being overlooked, or whether the market has already priced in …
The bigger question is whether it can turn a capital-light outsourcing model into something more ambitious. Construction of its first owned surgical hub in Scunthorpe, costed at £8m to £9m, is under way, and three long-term NHS contracts now underpin roughly 80% of activity. …
First-half revenue reached $3,097m, up 4.6% on a reported basis and 2.3% underlying. The more telling numbers sat below the revenue line. Trading profit rose 8.1% to $566m, lifting the tradingMargin60 basis points to 18.3%, while adjustedEarnings Per Shareclimbed 11.0% to 47.7 cents. TheInterim …
Proteome Sciences offers contract proteomics services that support drug discovery, development and biomarker identification for pharmaceutical and academic clients, using proprietary techniques such as its TMT (tandem mass tag) reagent technology to analyse proteins in tissue, cell and body-fluid samples. It's a specialist, nicheBusinessserving …
TheraCryf's investment case rests almost entirely on Ox-1, its lead drug candidate targeting addiction. Through 2026 the company has reported a series of incremental milestones:Manufacturingscale-up work, completion of dosing in rodent toxicology studies, and progress described by the company as 'ahead of plan', with …
On 3 September 2026, Futura Medical announced a retail offer via the BookBuild platform, issuing up to 75 million new ordinary shares at 0.2 pence each to raise approximately £150,000 from existing UK shareholders, at a discount of around 37.6% to the prior closing …
ImmuPharma has not published a single blockbuster announcement in recent weeks, but it has delivered a steady drumbeat of operational updates on Kapiglucagon, its glucagon-based programme aimed at severe hypoglycaemia. In May the company confirmed it had initiated an IND-enabling programme, before appointing Bachem …